Last reviewed · How we verify
JYP0061
At a glance
| Generic name | JYP0061 |
|---|---|
| Also known as | Experimental Drug Group |
| Sponsor | Guangzhou JOYO Pharma Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis (PHASE2)
- A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD) (PHASE2)
- Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JYP0061 CI brief — competitive landscape report
- JYP0061 updates RSS · CI watch RSS
- Guangzhou JOYO Pharma Co., Ltd portfolio CI